5-Year Survival of Non-Small Cell Lung Cancer Patients after Adjuvant Chemoimmunoradiotherapy Oleg Kshivets, M.D., Ph.D. D...
Abstract: <ul><li>FIVE-YEAR SURVIVAL AND LIFE SPAN OF NON-SMALL CELL LUNG CANCER PATIENTS AFTER  </li></ul><ul><li>ADJUVAN...
Samplings: <ul><li>Lung Cancer Patients Lived More than 5 Years after Complete Resections..…... 242 </li></ul><ul><li>Lung...
Samplings: <ul><li>Adjuvant Chemoimmunoradiotherapy………….. 54 </li></ul><ul><li>Postoperative Radiotherapy..……...….. 86 </l...
Radical Procedures: <ul><li>Pneumonectomy…………………..175 </li></ul><ul><li>Upper/Lower Bilobectomy…………21 </li></ul><ul><li>Up...
Staging: <ul><li>T1…..118  N0..…223  G1…..100 </li></ul><ul><li>T2…..187  N1……97  G2…..104 </li></ul><ul><li>T3……84  N2……8...
5-Year Survivors and Losts
Results of Factor Analysis
Results of Factor Analysis
Nucloids of Lung Cancer Patients with N0-2, n=404
Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N0-2, n=404
Nucloids of Lung Cancer Patients with N1-2, n=181
Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N1-2, n=181
Network-Model of Lung Cancer Patients  with N0-2 (n=404)
Network-Model of Lung Cancer Patients  with N0 (n=223)
Network-Model of Lung Cancer Patients with N1-2 (n=181)
Survival of Lung Cancer Patients with N0-2 (n=404)
Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N0-2, n=404
Logistic Regression Model of Lung Cancer Patients with N0-2, n=404
Logistic Regression Model of Lung Cancer Patients with N0-2, n=404
SEPATH-Model: Clinicopathologic Characteristics-Survival of Lung Cancer Patients with N0-2 metastases (n=404)
Survival of Lung Cancer Patients with N0-2 (n=404)
Survival of Lung Cancer Patients with N1-2 (n=181)
Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N1-2, n=181
Logistic Regression Model of Lung Cancer Patients with N1-2, n=181
Logistic Regression Model of Lung Cancer Patients with N1-2, n=181
SEPATH-Model: Clinicopathologic Characteristics-Survival of Lung Cancer Patients with N1-2 metastases (n=181)
Results of Monte Carlo Simulation
Life Span of Died Lung Cancer Patients with N0-2 (n=162)
Conclusions: <ul><li>Adjuvant chemoimmunoradiotherapy significantly improved 5-year survival and life span of non-small ce...
Address: <ul><li>Oleg Kshivets, M.D., Ph.D. </li></ul><ul><li>Consultant Thoracic/Abdominal Surgeon </li></ul><ul><li>Depa...
Upcoming SlideShare
Loading in …5
×

Kshivets O. Lung Cancer Surgery

980 views

Published on

5-Year Survival of Non-Small Cell Lung Cancer Patients after Adjuvant Chemoimmunoradiotherapy

Published in: Health & Medicine

Kshivets O. Lung Cancer Surgery

  1. 1. 5-Year Survival of Non-Small Cell Lung Cancer Patients after Adjuvant Chemoimmunoradiotherapy Oleg Kshivets, M.D., Ph.D. Department of Surgery, Siauliai Public Hospital, Lithuania The 53 rd Annual Cancer Symposium of Society of Surgical Oncology New Orleans, The USA, 2000
  2. 2. Abstract: <ul><li>FIVE-YEAR SURVIVAL AND LIFE SPAN OF NON-SMALL CELL LUNG CANCER PATIENTS AFTER </li></ul><ul><li>ADJUVANT CHEMOIMMUNORADIOTHERAPY </li></ul><ul><li>O.Kshivets* Siauliai Cancer Center, Siauliai, Lithuania </li></ul><ul><li>  </li></ul><ul><li>Purpose : This study aimed to determine expediency of adjuvant chemoimmunoradiotherapy (AT) for radical operated non-small cell lung cancer (C) patients (LCP) with pathologic stage II-III (T1-4N0-2M0G1-3). </li></ul><ul><li>Methods : In randomised trial (1985-1998) 5-year survival (5YS) of 54 radical operated LCP after AT (age=54.4  1.0 years; males=49, females=5; C size=4.7  0.2 cm) was compared with 5YS of 264 LCP after radical procedures (S) (age=55.8  0.5 years; males=240, females=24; C size=4.5  0.1 cm) and with 5YS of 86 radical operated LCP after postoperative radiation (R) (45-50 Gy) (age=58.0  0.8 years; males=74, females=12; C size=4.7  0.2 cm). Variables selected for 5YS study were sex, age, TNMG, cell type, C size. 1 cycle of chemoimmunotherapy (CAVT: cyclophosphamid 500 mg/m 2 IV+doxorubicin 50 mg/m 2 IV+vincristin 1.4 mg/m 2 IV on day 1; thymalin/taktivin 20 mg IM daily for 5 days) was given on 10-14 day after S. R (45-50 Gy) was administered since 7 day after 1 cycle. After R 3-4 courses of CAVT were repeated every 21-28 day. Representativeness of samplings was reached by means of randomisation based on unrepeated random selection. Multiple correspondence analysis (A), cluster A, confirmatory factor A, structural equation modeling, Monte Carlo simulation were used to determine any significant overall differences between survival of LCP after AT, S, R. </li></ul><ul><li>Results : 5YS was superior in AT group (64.8%: 35 from 54 LCP with N0-2; life span: LS=1998.2  156.9 days) compared with R group (45.3%: 39 from 86 LCP with N0-2; LS=1296.4  109.5 days) (P<0.001). 5YS of S group was 63.6% (168 from 264 LCP with N0-2; LS=1738.3  63.4 days) (P>0.05 for AT and P<0.001 for R). For LCP with N1-2 5YS was significantly superior for AT group (63.6%: 21 from 33; LS=1934.0  189.9 days) compared with S group (28.1%: 25 from 89; LS=1056.9  91.1 days) (P<0.001) and with R group (35.6%: 21 from 59; LS=1051.7  119.6 days) (P<0.001). Rates of age, sex, T1-4, G1-3, cell type, C size for LCP after AT, S and R were not significantly different. Structural equation modeling and Monte Carlo simulation confirmed significant overall differences between 5YS (P<0.05) and LS (P<0.001) of LCP with N1-2 after AT with respect to S or R; however, 5YS of LCP for N0 with or without AT and R were not significantly different. </li></ul>
  3. 3. Samplings: <ul><li>Lung Cancer Patients Lived More than 5 Years after Complete Resections..…... 242 </li></ul><ul><li>Lung Cancer Patients Died Because Generalization During First 5 Years after Complete Resections.…….…………... 162 </li></ul><ul><li>In All…………………………………...404 </li></ul>
  4. 4. Samplings: <ul><li>Adjuvant Chemoimmunoradiotherapy………….. 54 </li></ul><ul><li>Postoperative Radiotherapy..……...….. 86 </li></ul><ul><li>Surgery Alone………………………… 264 </li></ul><ul><li>In All…………………………………...404 </li></ul>
  5. 5. Radical Procedures: <ul><li>Pneumonectomy…………………..175 </li></ul><ul><li>Upper/Lower Bilobectomy…………21 </li></ul><ul><li>Upper Lobectomy…………………136 </li></ul><ul><li>Lower Lobectomy………………….66 </li></ul><ul><li>Middle Lobectomy………………….6 </li></ul><ul><li>Combined Procedures……………..49 </li></ul><ul><li>In All…………………………...….404 </li></ul>
  6. 6. Staging: <ul><li>T1…..118 N0..…223 G1…..100 </li></ul><ul><li>T2…..187 N1……97 G2…..104 </li></ul><ul><li>T3……84 N2……84 G3…..200 </li></ul><ul><li>T4……15 Stage II...111 Stage III...293 </li></ul><ul><li>Squamous Cell Carcinoma…..……….263 </li></ul><ul><li>Adenocarcinoma………………………116 </li></ul><ul><li>Large Cell Carcinoma………………….25 </li></ul>
  7. 7. 5-Year Survivors and Losts
  8. 8. Results of Factor Analysis
  9. 9. Results of Factor Analysis
  10. 10. Nucloids of Lung Cancer Patients with N0-2, n=404
  11. 11. Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N0-2, n=404
  12. 12. Nucloids of Lung Cancer Patients with N1-2, n=181
  13. 13. Results of Cluster-Analysis of Clinicopathologic Characteristics of Lung Cancer Patients with N1-2, n=181
  14. 14. Network-Model of Lung Cancer Patients with N0-2 (n=404)
  15. 15. Network-Model of Lung Cancer Patients with N0 (n=223)
  16. 16. Network-Model of Lung Cancer Patients with N1-2 (n=181)
  17. 17. Survival of Lung Cancer Patients with N0-2 (n=404)
  18. 18. Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N0-2, n=404
  19. 19. Logistic Regression Model of Lung Cancer Patients with N0-2, n=404
  20. 20. Logistic Regression Model of Lung Cancer Patients with N0-2, n=404
  21. 21. SEPATH-Model: Clinicopathologic Characteristics-Survival of Lung Cancer Patients with N0-2 metastases (n=404)
  22. 22. Survival of Lung Cancer Patients with N0-2 (n=404)
  23. 23. Survival of Lung Cancer Patients with N1-2 (n=181)
  24. 24. Proportional Hazard (Cox) Regression Model of Lung Cancer Patients with N1-2, n=181
  25. 25. Logistic Regression Model of Lung Cancer Patients with N1-2, n=181
  26. 26. Logistic Regression Model of Lung Cancer Patients with N1-2, n=181
  27. 27. SEPATH-Model: Clinicopathologic Characteristics-Survival of Lung Cancer Patients with N1-2 metastases (n=181)
  28. 28. Results of Monte Carlo Simulation
  29. 29. Life Span of Died Lung Cancer Patients with N0-2 (n=162)
  30. 30. Conclusions: <ul><li>Adjuvant chemoimmunoradiotherapy significantly improved 5-year survival and life span of non-small cell lung cancer patients with N1-2 metastases after complete resections compared with surgery alone and postoperative radiotherapy. </li></ul><ul><li>One must be careful in using adjuvant chemoimmunoradiotherapy for lung cancer patients without lymph node metastases. </li></ul>
  31. 31. Address: <ul><li>Oleg Kshivets, M.D., Ph.D. </li></ul><ul><li>Consultant Thoracic/Abdominal Surgeon </li></ul><ul><li>Department of Surgery </li></ul><ul><li>Siauliai Public Hospital </li></ul><ul><li>Tilzes:42-16, LT78206, Siauliai, Lithuania </li></ul><ul><li>tel (37041)416614 </li></ul><ul><li>e-mail: [email_address] </li></ul>

×